British Journal of Cancer
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Timeliness of diagnosis and treatment: the challenge of childhood cancers.
125:1612-1620.
2021
-
Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers.
125:1178-1178.
2021
-
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
124:1503-1512.
2021
-
The association between colorectal cancer and prior antibiotic prescriptions: case control study.
122:912-917.
2020
-
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
121:15-21.
2019
-
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
119:707-712.
2018
-
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
118:1434-1441.
2018
-
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.
118:1238-1242.
2018
-
The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.
118:1399-1405.
2018
-
A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
119:508-516.
2018
-
Evaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis.
116:540-545.
2017
-
Impact of cause of death adjudication on the results of the European prostate cancer screening trial.
116:141-148.
2017
-
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study.
114:1160-1164.
2016
-
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.
114:616-622.
2016
-
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
114:631-637.
2016
-
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.
113:722-728.
2015
-
18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
112:1737-1743.
2015
-
The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy.
112:636-643.
2015
-
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
111:2262-2267.
2014
-
Refinement of the Symptom Screening in Pediatrics Tool (SSPedi).
111:1262-1268.
2014
-
Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis.
110:2593-2603.
2014
-
Validation of the Children’s International Mucositis Evaluation Scale (ChIMES) in paediatric cancer and SCT.
109:2515-2522.
2013
-
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
109:943-949.
2013
-
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
108:2021-2032.
2013
-
Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.
108:327-333.
2013
-
Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.
106:1626-1637.
2012
-
Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia.
105:1469-1473.
2011
-
Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer.
105:1458-1464.
2011
-
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies.
105:709-722.
2011
-
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
105:44-52.
2011
-
Statistical issues in the use of dynamic allocation methods for balancing baseline covariates.
104:1711-1715.
2011
-
Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.
104:1377-1383.
2011
-
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
104:756-762.
2011
-
Family history and the risk of gastric cancer.
102:237-242.
2010
-
Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador.
100:1026-1031.
2009
-
Identification of paediatric cancer patients with poor quality of life.
100:82-88.
2009
-
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study.
97:302-307.
2007
-
Bisphosphonates: are they standard of care for the treatment of breast cancer?.
96:1781-1782.
2007
-
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
96:1526-1531.
2007
-
Have we been guilty of ageism in the primary treatment of breast cancer?.
96:1011-1012.
2007
-
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.
94:1452-1459.
2006
-
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.
94:1136-1143.
2006
-
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.
94:1011-1015.
2006
-
Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid.
92:298-304.
2005
-
Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer.
91:1301-1307.
2004
-
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.
90:1429-1436.
2004
-
Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells.
89:2277-2283.
2003
-
Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity.
89:1979-1986.
2003
-
Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition.
89:954-954.
2003
-
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.
89:1031-1034.
2003
-
European cooperation for clinical practice guidelines in cancer.
89:S1-S3.
2003
-
Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancer.
89:385-390.
2003
-
A proliferation-dependent bystander effect in primary porcine and human urothelial explants in response to targeted irradiation.
88:767-774.
2003
-
Particulate debris from a titanium metal prosthesis induces genomic instability in primary human fibroblast cells.
88:548-552.
2003
-
Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease.
87:1234-1245.
2002
-
Risk factors for oesophageal, lung, oral and laryngeal cancers in black South Africans.
86:1751-1756.
2002
-
A controlled ‘before-after’ study: impact of a clinical guidelines programme and regional cancer network organization on medical practice.
86:313-321.
2002
-
‘Background to clinical guidelines in cancer’: SOR, a programmatic approach to guideline development and aftercare.
84:1-3.
2001
-
Production of a signal by irradiated cells which leads to a response in unirradiated cells characteristic of initiation of apoptosis.
83:1223-1230.
2000
-
True.
82:1740-1746.
2000
-
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
82:1427-1432.
2000
-
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions.
82:361-367.
2000
-
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
81:490-495.
1999
-
Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation.
77:1429-1438.
1998
-
The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer.
75:1534-1542.
1997
-
A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.
75:1014-1020.
1997
-
Erratum: The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy.
74:1691-1691.
1996
-
p53 protein is absent from the serum of patients with lung cancer.
74:1434-1440.
1996
-
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.
74:1242-1247.
1996
-
A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre.
73:1588-1593.
1996
-
The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy.
73:332-343.
1996
-
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
72:720-727.
1995
-
Prostate-specific antigen in serum of women with breast cancer.
72:728-731.
1995
-
Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients.
71:25-29.
1995
-
The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia.
67:1047-1052.
1993
-
A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance.
66:781-786.
1992
-
The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial.
65:737-743.
1992
-
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation.
65:130-132.
1992
-
Reversal of intrinsic multidrug resistance in Chinese hamster ovary cells by amiloride analogs.
63:247-251.
1991
-
Endocrine disorders following treatment of childhood brain tumours.
61:622-625.
1990
-
Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells.
61:568-572.
1990
-
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?.
59:910-914.
1989
-
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
58:779-782.
1988
-
Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line.
58:441-447.
1988
-
Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour.
58:415-418.
1988
-
Double antibody radioimmunoassay for monitoring metastatic breast cancer.
58:362-367.
1988
-
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
57:94-99.
1988
-
Cellular heterogeneity in normal and neoplastic human urothelium: A study using murine monoclonal antibodies.
56:439-444.
1987
-
DNA quaternary structure in the radiation sensitivity of human lymphocytes--a proposed role of copper..
8:141-144.
1987
-
RADIATION TRANSFORMATION IN DIFFERENTIATED HUMAN-CELLS IN CULTURE.
53:251-252.
1986
-
Evaluation of screening programmes for gynaecological cancer.
52:669-673.
1985
-
Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol.
48:873-876.
1983
-
Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: A study of active intervention.
44:267-269.
1981
-
Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy.
32:323-330.
1975
-
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
2006
-
Hypoxia inducible factor (HIF)-1 alpha in non-small cell lung cancer (NSCLC)
2002
-
beta-catenin in non-small cell lung cancer (NSCLC)
2002
-
Effects of low level radiation in normal urothelial cells
1999
-
Prognostic significance of platelet microvessel counts in non-small cell lung cancer
1999
-
CHANGES IN PROTEIN EXPRESSION DURING MELANOMA DIFFERENTIATION DETERMINED BY COMPUTER-ANALYSIS OF 2-D GELS
1990
-
CISPLATIN INVOKED LEAD MOBILIZATION STUDIES
1990
-
DEVELOPMENT OF A TECHNIQUE FOR OPTIMIZING CANCER-THERAPY USING A HUMAN EPITHELIAL MODEL SYSTEM
1988
-
LETHAL MUTATIONS AND THEIR EFFECT ON THE APPLICATION OF RADIOBIOLOGICAL RESULTS TO RADIOTHERAPY
1988
-
ENDOCRINE DISORDERS FOLLOWING TREATMENT OF BRAIN-TUMORS IN CHILDHOOD
1987
-
GROWTH FAILURE FOLLOWING IRRADIATION IN CHILDREN WITH BRAIN-TUMORS
1987
-
A HISTOPATHOLOGICAL AND DNA CYTOPHOTOMETRIC STUDY OF BENIGN AND MALIGNANT ESOPHAGEAL TISSUE CULTURED INVITRO
1987
-
A MODEL FOR THE STUDY OF TREATMENT RESPONSE IN HUMAN NORMAL AND TUMOR-CELLS INVITRO
1987
-
ANALYSIS OF THE HUMAN ANTI-MOUSE IG RESPONSE IN PATIENTS RECEIVING MURINE MONOCLONAL-ANTIBODIES
1986
-
LACK OF CORRELATION BETWEEN EXCISION REPAIR OF UV DAMAGE AND ADENOVIRUS REACTIVATION IN AN XP(D)-LIKE CELL-LINE
1986
-
RADIATION RESPONSE OF HUMAN ESOPHAGEAL CELLS-INVITRO
1986
-
HUMAN ANTI-MOUSE IMMUNOGLOBULIN RESPONSES IN PATIENTS RECEIVING MONOCLONAL-ANTIBODIES
1985
-
THE EFFECT OF ALTERED ENERGY-METABOLISM ON THE PRIMARY AND SECONDARY SURVIVAL-CURVE SHOULDER OF IRRADIATED CHO-KI CELLS
1984
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)